View Older Stories View More Recent Stories

Sep 17, 2026 04:32PM Form SCHEDULE 13D/A Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Sep 17, 2026 10:42AM BetterLife Pharma closes $100M public offering on Canadian exchange
Sep 17, 2026 09:27AM Lisata acquires Marea Therapeutics, raises $225M in private placement
Sep 15, 2026 07:01AM Serapha Bio names Kenneth Mills as CEO, eyes Nasdaq listing
Sep 14, 2026 06:45AM Tyra Biosciences prices $400 million stock offering at $22.03
Sep 3, 2026 05:11PM Form SCHEDULE 13G JATT III Acquisition Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 31, 2026 04:04PM Form N-PX RA CAPITAL MANAGEMENT, For: Jun 30
Aug 27, 2026 03:16PM JATT III Acquisition Corp closes $69M IPO on Nasdaq
Aug 25, 2026 04:44PM Court awards Biohaven and Yale $4M in trade secret case
Aug 21, 2026 08:00AM Gossamer Bio raises up to $250M in private placement for PAH drug
Aug 21, 2026 08:00AM Werewolf Therapeutics to merge with Ambros in $150M private placement
Aug 17, 2026 05:09PM Form SCHEDULE 13G Latigo Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 17, 2026 07:01AM Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Aug 14, 2026 06:38PM Form SCHEDULE 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 05:17PM Form SCHEDULE 13D/A Septerna, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:50PM Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:50PM Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:50PM Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:49PM Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:49PM Form SCHEDULE 13G/A GERON CORP Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:49PM Form SCHEDULE 13G/A Edgewise Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:49PM Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:48PM Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:48PM Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:48PM Form SCHEDULE 13G/A BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:48PM Form SCHEDULE 13G/A Atrium Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:48PM Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:45PM Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:44PM Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 14, 2026 04:37PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
Aug 13, 2026 04:16PM Form SCHEDULE 13G TCGX Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 11, 2026 04:40PM Form SCHEDULE 13D/A Wave Life Sciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 10, 2026 04:27PM Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 10, 2026 04:24PM Form SCHEDULE 13G Obsidian Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 7, 2026 04:14PM Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 6, 2026 05:50PM Form SCHEDULE 13G DBV Technologies S.A. Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 3, 2026 04:38PM Form SCHEDULE 13G Scribe Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 3, 2026 04:36PM Form SCHEDULE 13G CAPRICOR THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 3, 2026 09:00AM Obsidian Therapeutics completes Galera merger, raises $350M
Jul 31, 2026 04:34PM Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 29, 2026 07:30AM Processa acquires Vidya Therapeutics in $200M private placement deal
Jul 27, 2026 08:30AM Entera Bio prices $275M private placement led by BVF Partners
Jul 27, 2026 08:30AM Entera Bio prices $275 million private placement led by BVF Partners
Jul 27, 2026 07:01AM Jury awards Biohaven and Yale $4M in trade secret case
Jul 23, 2026 09:23PM Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 22, 2026 05:34PM Form SCHEDULE 13D/A Freenome, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 21, 2026 04:56PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 20, 2026 04:17PM Form SCHEDULE 13G AGENUS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 20, 2026 04:01PM Freenome begins trading on Nasdaq after $310M SPAC merger
Jul 17, 2026 05:53PM Form SCHEDULE 13G Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
View More Recent Stories View Older Stories